Search

Prediabetes and post-transplant diabetes mellitus affect about 20-30% of renal transplant patients. The latter is a risk factor for cardiovascular disease. However, no clear evidence linking prediabetes and cardiovascular disease is available. To study this we analyzed the impact of prediabetes on cardiovascular disease in 603 renal transplant patients followed with repeated oral glucose tests for up to five years and a long term survival evaluation. Prediabetes and post-transplant diabetes mellitus were defined at 12 months after transplantation to avoid their high reversibility rate before this period. 73 cardiovascular events were observed. The incidence of events was significantly higher in patients with either prediabetes, (17%; 0.023 person/year) or post-transplant diabetes mellitus (20%; 0.028 person/year) than in normal individuals, (7%; 0.0095 person/year). The incidence of events was comparable between prediabetes and post-transplant diabetes mellitus. Prediabetes at 12 months was a risk factor for cardiovascular events in univariate and multivariate Cox survival analyses (hazard ratio 2.24, 95% confidence interval 1.11-4.52). Prediabetes at three months and hemoglobin A1c at 12 months were not significantly associated with cardiovascular disease. Thus, prediabetes is a risk factor for cardiovascular disease in renal transplantation, a population at high risk for cardiovascular events. Since prediabetes is potentially a reversible condition, there is an opportunity to prevent cardiovascular disease in this population.

BACKGROUND The long-term clinical evolution of prediabetes and post-transplant diabetes mellitus (PTDM) is unknown. METHODS We analysed, in this cohort study, the reversibility, stability and progression of PTDM and prediabetes in 672 patients using repeated oral glucose tolerance tests (OGTTs) for ≤5 years. RESULTS Most patients were on tacrolimus, steroids and mycophenolate. About half developed either PTDM or prediabetes. The incidence of PTDM was 32% and bimodal: early PTDM (≤3 months) and late PTDM. Early PTDM reverted in 31%; late PTDM developed in patients with post-transplant prediabetes. The use of OGTTs was necessary to detect around half of PTDM. Pretransplant obesity was a major risk factor for early PTDM, for its persistence and for late PTDM {odds ratio [OR] 1.18 [95% confidence interval (CI) 1.09-1.28]}. At 3 months, higher HbA1c promoted [OR 2.37 (95% CI 1.38-4.06)], while insulin sensitivity protected against [OR 0.64 (95% CI 0.48-0.86)] late PTDM. At 3 months, 28% had prediabetes; of these, 36% remained stable, 43% normalized and 21% developed late PTDM. Pretransplant obesity [OR 1.20 (95% CI 1.04-1.39)] and higher HbA1c [OR 3.80 (95% CI 1.45-9.94)] at 3 months promoted while insulin sensitivity protected against [OR 0.57 (95% CI 0.34-0.95)] evolution from prediabetes to late PTDM. Immunosuppressive levels or acute rejection did not influence PTDM. Most (84%) of the patients with normal tests at 3 months remained stable without evolving into PTDM; 14% developed prediabetes. CONCLUSIONS PTDM and prediabetes are very common in renal transplantation. Classic metabolic factors like obesity, prediabetes and insulin resistance promote the evolution of PTDM and prediabetes. Patients with normal glucose metabolism rarely develop PTDM. OGTT is necessary to detect PTDM and prediabetes and thus should be included in clinical practice.

Background: Post-transplant diabetes mellitus (PTDM) is associated with poorer outcomes in kidney transplantation (KT) but little information exists about the evolution of traditional cardiovascular risk (CVR) factors under this disorder. Methods: We retrospectively analysed CVR factors at 3, 12 and 24 months of follow-up and mortality at three yr in 3365 KT performed in Spain during the years 1990, 1994 and 1998 with a functioning graft after the first year. Three groups were considered: (i) (PTDM, n, 251), (ii) diabetes mellitus as primary disease (DM, n = 156) and (iii) the remaining patients (controls, n = 2958). Results: Recipient age, weight and body mass index (BMI) were higher in PTDM than in the other groups (p

The increasing prevalence of pre-existing diabetes mellitus (DM) and especially the incidence of post-transplant diabetes mellitus (PTDM) is a disturbing tendency with far-reaching health and cost implications. We assessed the factors associated with PTDM and the impact of either condition on death-censored graft and patient survival.We studied 3365 adult kidney allograft recipients transplanted in 1990, 1994 and 1998, whose graft was functioning after 1 year of follow-up. Three groups were considered: Group I (DM; N = 156), Group II (PTDM; N = 251) and Group III (non-diabetic; N = 2958).Group I patients had been dialysed for shorter periods and received angiotensin-converting enzyme inhibitor (ACEI) or angiotensin-receptor blockers (ARB) therapy more frequently during follow-up than the other groups (P0.001). Mean age, body weight and body mass index (BMI) were greater in Group II patients than the other groups (P0.001). Group II showed lower rejection rates than Group III (P0.01). Risk factors for developing PTDM were recipient age60 years (OR = 2.24; P0.001), female recipient (OR = 1.5; P0.005), recipient weight65 kg (OR = 1.77; P0.002), BMI25 kg/m(2) (OR = 1.6; P0.04) or30 kg/m(2) (OR = 2.92; P0.005), and tacrolimus-based therapy (OR = 1.48; P0.05). Of note, the use of Sandimmune vs Neoral had a protective effect (OR = 0.7; P0.01). Using Cox's proportional hazards analysis, DM correlated with reduced death-censored graft survival (RR = 1.68; 95% CI = 1.14-2.47; P0.008), while PTDM correlated with reduced patient survival (RR = 1.55; 95% CI = 1.05-2.27; P0.02).One year after transplantation, DM was associated with a decrease in death-censored graft survival, while PTDM was an independent negative predictor of patient survival after kidney transplantation. New strategies to improve outcome are needed.